home drugs a-z list side effects drug center Benecid and colchicine (Benecid and colchicine) drug
Benecid and Colchicine Tablets USP
Tell your doctor if you have ever had any unusual or allergic reaction to Benecid or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Hematuria, renal colic, costovertebral pain, and formation of uric ac >DOSAGE AND ADMINISTRATION ). In these cases when alkali is administered, the acid-base balance of the patient should be watched.
Use with caution in patients with a history of peptic ulcer.
Benecid and colchicine has been used in patients with some renal impairment but dosage requirements may be increased. Benecid and colchicine may not be effective in chronic renal insufficiency particularly when the glomerular filtration rate is 30 mL/minute or less.
A reducing substance may appear in the urine of patients receiving Benecid. This disappears with discontinuance of therapy. Suspected glycosuria should be confirmed by using a test specific for glucose.
Adequate animal studies have not been conducted to determine the carcinogenicity potential of Benecid or this drug combination. Since colchicine is an established mutagen, its ability to act as a carcinogen must be suspected and administration of Benecid and colchicine should involve a weighing of the benefit-vs-risk when long-term administration is contemplated.
How should I take Benecid (Benemid)?
Follow all directions on your prescription label and read all medication guides or instruction sheets. Use the medicine exactly as directed.
Drink plenty of water to prevent kidney stones while you are taking Benecid.
You may be given other medications to also help prevent kidney stones. Keep using these medicines for as long as your doctor has prescribed.
If you need surgery, tell your surgeon you currently take Benecid. This medicine may affect your body's response to anesthesia.
Call your doctor if your gout symptoms do not improve, or if they get worse. Your doctor may prescribe an additional medicine called colchicine.
Store at room temperature away from moisture, heat, and light.
Central Nervous System: headache, dizziness.
Metabolic: precipitation of acute gouty arthritis.
Gastrointestinal:hepatic necrosis, vomiting, nausea, anorexia, sore gums.
Genitourinary: nephrotic syndrome, uric acid stones with or without hematuria, renal colic, costovertebral pain, urinary frequency.
Hematologic: aplastic anemia, leukopenia, hemolytic anemia which in some patients could be related to genetic deficiency of glucose-6-phosphate dehydrogenase in red blood cells, anemia.
Benecid and Colchicine Tablets USP 500 mg-0.5 mg are bisected, white, capsule-shaped tablets imprinted DAN DAN and 5325 supplied in bottles of 100.
Dispense in a well closed, light-resistant container with child-resistant closure.
Store at 20°-25°C (68°-77°F).
Protect from light.
Watson Laboratories, Inc. Corona, CA 92880 USA. FDA Rev date: 5/6/2002
Benecid crosses the placental barrier and appears in cord blood. Colchicine can arrest cell division in animals and plants. In certain species of animals under certain conditions, colchicines has produced teratogenic effects. The possibility of such effects in humans also has been reported. Because of the colchicine component, Benecid and colchicine is contraindicated in pregnant patients. The use of any drug in women of childbearing potential requires that the anticipated benefit be weighed against the possible hazards.
A Interval treatment: probenec >No safety studies of Benecid during pregnancy are available, but the drug has been used for decades without reports of specific adverse fetal effects, and is considered compatible for use during pregnancy when clearly indicated. As Benecid has no analgesic and anti-inflammatory activity, it is ineffective during an acute gout attack. There are no data for benzbromarone use during pregnancy. Benzbromarone use has been associated with severe, sometimes fatal hepatotoxicity in users.
Allopurinol is an uricostatic drug, which together with its major metabolite, oxypurinol, inhibits the enzyme xanthine ox > shown evidence of carcinogenicity or mutagenicity. In experimental animal studies allopurinol was not teratogenic in rabbits or rats, while an increased rate of cleft palate was observed in mice exposed during organogenesis ( Fujii 1972 ); human experience is limited. A recently published case report describes a newborn with multiple malformations after the mother had taken allopurinol throughout her pregnancy ( Kozenko 2011 ). Further, a recent case series describes 31 pregnancies exposed to allopurinol in the first trimester. Even if the overall rate of spontaneous abortions and malformations in this small series was not higher than expected, one child was reported to have severe malformations including micropthalmia, cleft lip and palate, renal hypoplasia, low-set ears, hearing deficit, bilateral cryptorchidism and micropenis ( Hoeltzenbein 2013 ). The pattern of anomalies was similar to those described by Kozenko (2011) and according to the authors, could be a signal for allopurinol teratogenicity, possibly mediated by the drug’s capacity to interfere with purine metabolism. Use of allopurinol during the third trimester has not been associated with adverse outcomes, and antenatally administered allopurinol has even been proposed as a potential agent to prevent hypoxic-ischaemic brain injury because of the drug’s capacity to prevent free radical formation, and thereby possibly reducing hypoxic-reperfusion damage ( Kaandorp 2010b ).
Febuxostat is a recently introduced uricostatic agent, blocking xanthine oxidase similarly as allopurinol. No teratogenicity was observed in animal studies but there are no data for use during pregnancy in humans.
Pegloticase and rasburicase catalyze the enzymatic oxidation of uric acid to allantoin, a water-soluble substance that is easily eliminated via the kidneys. Pegloticase is indicated for gout refractory to conventional treatment. Rasburicase is used for hyperuricemia caused by hematologic malignancies. There is no experience of either drug for use during pregnancy.
What should I discuss with my healthcare prov >
You should not use this medication if you are allergic to Benecid, or if you have:
- uric acid kidney stones;
- a gout attack that has already started; or
- a blood cell disorder such as anemia, or decreased white blood cells.
Before taking Benecid, tell your doctor if you are allergic to any drugs, or if you have:
- kidney disease;
- a history of stomach ulcer; or
- if you have ever had kidney stones.
If you have any of these conditions, you may need a dose adjustment or special tests to safely take Benecid.
Benecid may be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment.
It is not known whether Benecid passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.
Benecid should not be given to a child younger than 2 years old.
Why is this medication prescribed?
Benecid is used to treat chronic gout and gouty arthritis. It is used to prevent attacks related to gout, not treat them once they occur. It acts on the kidneys to help the body eliminate uric acid. Benecid is also used to make certain antibiotics more effective by preventing the body from passing them in the urine.
This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.
Probenec > Benecid is a urate transporter-1 (URAT-1) inhibitor, increasing uric acid excretion via inhibition of tubular reabsorption of oxypurinol, the active metabolite of allopurinol. 13 Combination of an XOI with a uricosuric drug is recommended by the American College of Rheumatology and European League Against Rheumatism guidelines in patients who have not achieved target SU levels. 2,14 Benecid is usually started at 500 mg twice daily and increased in a stepwise fashion to reach SU target and is usually used in doses of up to 2000 mg/day. It is more effective as twice/thrice daily dose, which can raise compliance issues. 15 Benecid is not recommended in patients with CrCl 16
Probenec >Benecid is a uricosuric and renal tubular blocking agent. It inhibits the tubular reabsorption of urate, thus increasing the urinary excretion of uric acid and decreasing serum urate levels. Effective uricosuria reduces the miscible urate pool, retards urate deposition, and promotes resorption of urate deposits.
Benecid inhibits the tubular secretion of penicillin and usually increases penicillin plasma levels by any route the antibiotic is given. A 2-fold to 4-fold elevation has been demonstrated for various penicillins.
Benecid also has been reported to inhibit the renal transport of many other compounds including aminohippuric acid (PAH), aminosalicylic acid (PAS), indomethacin, sodium iodomethamate and related iodinated organic acids, 17-ketosteroids, pantothenic acid, phenolsulfonphthalein (PSP), sulfonamides, and sulfonylureas. See also Drug Interactions.
Benecid decreases both hepatic and renal excretion of sulfobromophthalein (BSP). The tubular reabsorption of phosphorus is inhibited in hypoparathyroid but not in euparathyroid individuals.
Benecid does not influence plasma concentrations of salicylates, nor the excretion of streptomycin, chloramphenicol, chlortetracycline, oxytetracycline, or neomycin.
The mode of action of colchicine in gout is unknown. It is not an analgesic, though it relieves pain in acute attacks of gout. It is not a uricosuric agent and will not prevent progression of gout to chronic gouty arthritis. It does have a prophylactic, suppressive effect that helps to reduce the incidence of acute attacks and to relieve the residual pain and mild discomfort that patients with gout occasionally feel.
In man and certain other animals, colchicine can produce a temporary leukopenia that is followed by leukocytosis. Colchicine has other pharmacologic actions in animals: It alters neuromuscular function, intensifies gastrointestinal activity by neurogenic stimulation, increases sensitivity to central depressants, heightens response to sympathomimetic compounds, depresses the respiratory center, constricts blood vessels, causes hypertension by central vasomotor stimulation, and lowers body temperature.